Influenza vaccination for older adults

Influenza vaccines were developed in the 1930s and were shown in randomized clinical trials to prevent influenza in young healthy adults. The significant morbidity and mortality associated with influenza in adults, age 65 y and older, prompted the early recommendation for influenza vaccination in th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Human vaccines & immunotherapeutics Ročník 8; číslo 1; s. 96 - 101
Hlavní autoři: Talbot, H. Keipp B., Libster, Romina, Edwards, Kathryn
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Taylor & Francis 01.01.2012
Témata:
adjuvants
Aged
Aged, 80 and over
Binding
Biology
Bioscience
Calcium
Cancer
Cell
Cycle
effectiveness
efficacy
elderly
frailty
Hospitalization - statistics & numerical data
Humans
influenza
Influenza A Virus, H1N1 Subtype - immunology
Influenza A Virus, H3N2 Subtype - immunology
Influenza B virus - immunology
influenza vaccine
Influenza Vaccines - immunology
Influenza, Human - epidemiology
Influenza, Human - immunology
Influenza, Human - prevention & control
Landes
Organogenesis
Proteins
Randomized Controlled Trials as Topic
Treatment Outcome
Vaccination
Vaccines, Attenuated - immunology
ISSN:2164-5515, 2164-554X, 2164-554X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Influenza vaccines were developed in the 1930s and were shown in randomized clinical trials to prevent influenza in young healthy adults. The significant morbidity and mortality associated with influenza in adults, age 65 y and older, prompted the early recommendation for influenza vaccination in that age group, based on efficacy data in younger adults. Subsequently a number of studies have demonstrated vaccine effectiveness in older adults, but it appears to be lower than in younger adults. New vaccines are being developed with enhanced immunogenicity to improve the protection of older adults. In the meantime, the currently licensed influenza vaccines need to be administered annually to prevent the estimated 90,000 hospitalizations and 5,000 deaths attributed to influenza in adults ≥65 y of age each year.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.4161/hv.8.1.18129